On standardized relative survival.
MetadataShow full item record
Cancer survival comparisons between cohorts are often assessed by estimates of relative or net survival. These measure the difference in mortality between those diagnosed with the disease and the general population. For such comparisons methods are needed to standardize cohort structure (including age at diagnosis) and all-cause mortality rates in the general population. Standardized non-parametric relative survival measures are evaluated by determining how well they (i) ensure the correct rank ordering, (ii) allow for differences in covariate distributions, and (iii) possess robustness and maximal estimation precision. Two relative survival families that subsume the Ederer-I, Ederer-II, and Pohar-Perme statistics are assessed. The aforementioned statistics do not meet our criteria, and are not invariant under a change of covariate distribution. Existing methods for standardization of these statistics are either not invariant to changes in the general population mortality or are not robust. Standardized statistics and estimators are developed to address the deficiencies. They use a reference distribution for covariates such as age, and a reference population mortality survival distribution that is recommended to approach zero with increasing age as fast as the cohort with the worst life expectancy. Estimators are compared using a breast-cancer survival example and computer simulation. The proposals are invariant and robust, and out-perform current methods to standardize the Ederer-II and Pohar-Perme estimators in simulations, particularly for extended follow-up.
AuthorsSasieni, P; Brentnall, AR
- College Publications 
Showing items related by title, author, creator and subject.
Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bachanova, V; Burns, LJ; Wang, T; Carreras, J; Gale, RP; Wiernik, PH; Ballen, KK; Wirk, B; Munker, R; Rizzieri, DA;... (2015-02)Alternative donor transplantation is increasingly used for high-risk lymphoma patients. We analyzed 1593 transplant recipients (2000-2010) and compared transplant outcomes in recipients of 8/8 allele HLA-A, -B, -C and DRB1 ...
Vasiljević, N; Ahmad, AS; Carter, PD; Fisher, G; Berney, DM; Foster, CS; Cuzick, J; Lorincz, AT (2014)AIM: We investigated if methylation of candidate genes can be useful for predicting prostate cancer (PCa) specific death. PATIENTS & METHODS: Methylation of PITX2, WNT5a, SPARC, EPB41L3 and TPM4 was investigated in a 1:2 ...
Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. Rohatiner, AZS; Smith, ML; Spinelli, O; Rambaldi, A; Bassan, R; di Bona, E; Rodeghiero, F; Raimondi, R; Björkholm, M; Johnson, S;... (2014-12)